Help Privacy Policy Disclaimer
  Advanced SearchBrowse




Journal Article

Diabetes mellitus as a risk factor for Parkinson's disease: a molecular point of view


Outeiro,  Tiago F.
Experimental Neurodegeneration, Max Planck Institute of Experimental Medicine, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available

Biosa, A., Outeiro, T. F., Bubacco, L., & Bisaglia, M. (2018). Diabetes mellitus as a risk factor for Parkinson's disease: a molecular point of view. Molecular Neurobiology, 55, 8754-8763. doi:10.1007/s12035-018-1025-9.

Cite as: https://hdl.handle.net/21.11116/0000-0002-55B2-5
Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by elevated concentrations of glucose in the blood. The chronic hyperglycemic state accounts for most of the vascular complications associated to the disease and the prevalent mechanism proposed is related to the glycating chemistry mediated by methylglyoxal (MG), which accumulates in T2DM. In recent years, a higher risk of Parkinson’s disease (PD) onset in people affected by T2DM has become evident, but the molecular mechanisms underlying the interplay between T2DM and PD are still unknown. The oxidative chemistry of dopamine and its reactivity towards the protein α-Synuclein (aS) has been associated to the pathogenesis of PD. Recently, aS has also been described to interact with MG. Interestingly, MG and the dopamine oxidation products share both structural similarity and chemical reactivity. The ability of MG to spread over the site of its production and react with aS could represent the rationale to explain the higher incidence of PD in T2DM-affected people and may open opportunities for the development of novel strategies to antagonize the raise of PD.